Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Sep. 30, 2025	Sep. 30, 2024
Expenses:
Research and development	$ 3,668,738	$ 2,881,967
General and administrative	4,242,828	4,132,777
Loss from operations	(7,911,566)	(7,014,744)
Other income :
Reimbursement grant income	783,894	698,277
Interest income	2,558	153,498
Misc other income	0	14,766
Foreign exchange loss	(59,609)	(21,042)
Nonoperating Income (Expense)	726,843	845,499
Loss before income taxes	(7,184,723)	(6,169,245)
Income tax expense	800	800
Net loss	(7,185,523)	(6,170,045)
Exchange differences on translation	76,842	(27,965)
Net comprehensive loss	$ (7,108,681)	$ (6,198,010)
Weighted average number of common shares (in shares)	5,676,708	3,197,423
Loss per common share - basic and diluted (in dollars per share)	$ (1.27)	$ (1.93)